MX377208B - Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. - Google Patents

Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Info

Publication number
MX377208B
MX377208B MX2018000239A MX2018000239A MX377208B MX 377208 B MX377208 B MX 377208B MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 377208 B MX377208 B MX 377208B
Authority
MX
Mexico
Prior art keywords
formula
agents
theranosmotic
biphosphonates
hbed
Prior art date
Application number
MX2018000239A
Other languages
English (en)
Other versions
MX2018000239A (es
Inventor
Hank F Kung
Karl Ploessl
Seok Rye Choi
Zehui Wu
Zhihao Zha
Original Assignee
Five Eleven Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Eleven Pharma Inc filed Critical Five Eleven Pharma Inc
Publication of MX2018000239A publication Critical patent/MX2018000239A/es
Publication of MX377208B publication Critical patent/MX377208B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3817—Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiology & Medical Imaging (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de acuerdo con la formula I o formula II que son agentes de toma de imágenes óseas potenciales; ciertos compuestos etiquetados con 68Ga mostraron excelente captación y retención ósea; la presente invención también se refiere a composiciones farmacéuticas que comprenden un portador farmacéuticamente aceptable y un compuesto de formula I o formula II o una sal farmacéuticamente aceptable del mismo.(ver formula I y formula II)
MX2018000239A 2015-07-07 2016-07-06 Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. MX377208B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189652P 2015-07-07 2015-07-07
US201662320296P 2016-04-08 2016-04-08
PCT/US2016/041040 WO2017007790A1 (en) 2015-07-07 2016-07-06 Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents

Publications (2)

Publication Number Publication Date
MX2018000239A MX2018000239A (es) 2018-05-23
MX377208B true MX377208B (es) 2025-03-07

Family

ID=57685907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000239A MX377208B (es) 2015-07-07 2016-07-06 Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Country Status (11)

Country Link
US (1) US10253052B2 (es)
EP (1) EP3319643B1 (es)
JP (1) JP6792875B2 (es)
KR (1) KR102651945B1 (es)
CN (1) CN107847618B (es)
AU (1) AU2016289474C1 (es)
DK (1) DK3319643T3 (es)
EA (1) EA201890221A1 (es)
IL (1) IL256726A (es)
MX (1) MX377208B (es)
WO (1) WO2017007790A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6792875B2 (ja) 2015-07-07 2020-12-02 ファイブ イレブン ファーマ インコーポレイテッド Ｈｂｅｄ−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用
TW201832750A (zh) * 2017-03-02 2018-09-16 美商５１１製藥公司 放射性藥品標記裝置
US11723992B2 (en) * 2018-08-03 2023-08-15 Board Of Regents, The University Of Texas System Method for extraction and purification of 68GA
CN109438517B (zh) * 2018-12-27 2021-01-08 北京久杰净化工程技术有限公司 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法
CA3137963A1 (en) * 2019-04-26 2020-10-29 Five Eleven Pharma Inc. Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents
WO2021067513A1 (en) * 2019-10-01 2021-04-08 City Of Hope Metal chelating agents and methods of using the same
DE102021101216A1 (de) * 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
DE102022105175A1 (de) * 2022-03-04 2023-09-07 Atoms for Cure GmbH Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik
CN119060094B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院（广州呼吸中心） 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用
CN119060093B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院（广州呼吸中心） 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133872A1 (en) * 2001-10-22 2003-07-17 Kiefer Garry E. Radiopharmaceutical agent for the treatment of early stage cancer
JP2006523237A (ja) * 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
US7161000B2 (en) * 2003-05-30 2007-01-09 Sumitomo Chemical Company, Limited Method for producing phenol condensate
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CN104774175B (zh) * 2007-06-26 2019-04-16 约翰·霍普金斯大学 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
WO2011021390A1 (ja) * 2009-08-20 2011-02-24 富士フイルムＲｉファーマ株式会社 ビスホスホン酸誘導体及びその放射性金属核種標識体
EP2697347B1 (en) * 2011-04-13 2016-11-16 Firmenich SA Equilibrated dynamic mixtures to control the release of perfuming aldehydes and ketones
ITMI20121156A1 (it) 2012-06-29 2013-12-30 Consiglio Nazionale Ricerche Metodo di elaborazione di immagini di tomografia a coerenza ottica
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP6792875B2 (ja) 2015-07-07 2020-12-02 ファイブ イレブン ファーマ インコーポレイテッド Ｈｂｅｄ−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用

Also Published As

Publication number Publication date
WO2017007790A1 (en) 2017-01-12
CN107847618B (zh) 2021-07-16
AU2016289474A1 (en) 2018-02-01
EP3319643A1 (en) 2018-05-16
WO2017007790A9 (en) 2018-01-04
JP2018524352A (ja) 2018-08-30
HK1254864A1 (en) 2019-07-26
KR102651945B1 (ko) 2024-03-26
DK3319643T3 (da) 2020-06-15
AU2016289474C1 (en) 2021-04-08
US20170022224A1 (en) 2017-01-26
EP3319643B1 (en) 2020-04-22
JP6792875B2 (ja) 2020-12-02
MX2018000239A (es) 2018-05-23
KR20180026736A (ko) 2018-03-13
CA2991498A1 (en) 2017-01-12
IL256726A (en) 2018-03-29
CN107847618A (zh) 2018-03-27
EP3319643A4 (en) 2019-04-10
US10253052B2 (en) 2019-04-09
AU2016289474B2 (en) 2020-12-24
EA201890221A1 (ru) 2018-06-29

Similar Documents

Publication Publication Date Title
MX377208B (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
MX2024004531A (es) Compuestos de piridazinona y usos de los mismos.
ZA201906832B (en) Novel psma-binding agents and uses thereof
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
MX378155B (es) Derivados de 9h-pirrolo-dipiridina.
MX376639B (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer.
EA201691141A1 (ru) Соединения против ccr6
ECSP17069696A (es) Compuestos novedosos
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX382175B (es) Composiciones de profármaco de monometilfumarato
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
MX383577B (es) Derivados sustituidos de guanidina.

Legal Events

Date Code Title Description
FG Grant or registration